X4 Pharmaceuticals
XFOR
53 hedge funds and large institutions have $118M invested in X4 Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 6
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more capital invested
Capital invested by funds: $98.4M → $118M (+$19.9M)
8% more funds holding
Funds holding: 49 → 53 (+4)
0.21% more ownership
Funds ownership: 2.08% → 2.28% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$19.7M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$8.04M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.56M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.97M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.52M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.48M |
| 3 |
Millennium Management
New York
|
-$1.46M |
| 4 |
DM
Deerfield Management
New York
|
-$1.37M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$360K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $10K | +$7.89K | +22 | +244% |
|
|
PAM
52
Panagora Asset Management
Boston,
Massachusetts
| $5K | – | – | – |
|
|
PCM
53
Prelude Capital Management
New York
| $2K | +$2.51K | +7 | New |
|
54
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | – | – | – |
|
|
OAM
55
Oxford Asset Management
Oxford,
United Kingdom
| – | -$360K | -943 | Closed |
|
56
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$259K | -680 | Closed |
|
57
Russell Investments Group
London,
United Kingdom
| – | -$133K | -350 | Closed |
|
58
Victory Capital Management
San Antonio,
Texas
| – | -$25K | -66 | Closed |
|
XFOR Hedge Fund Activity: Q4 2019 in Review
53 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2019, worth a combined $118M — up 20% from $98.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XFOR positions and 4 closed out — a net gain of 9 holders — while 24 added to existing stakes and 6 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $19.7M. The largest seller was Cormorant Asset Management, cutting an estimated $7.52M.
- 53 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2019, up from 49 in Q3 2019.
- Funds reported $118M of X4 Pharmaceuticals stock for Q4 2019, up 20% quarter-over-quarter.
- 13 funds opened new X4 Pharmaceuticals positions in Q4 2019 and 4 closed out, a net change of +9 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2019 was Bain Capital Life Sciences Investors, an estimated $19.7M added.
- The largest X4 Pharmaceuticals seller in Q4 2019 was Cormorant Asset Management, an estimated $7.52M sold.
Based on aggregated 13F filings for Q4 2019.